{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:10:08Z","timestamp":1771924208286,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T00:00:00Z","timestamp":1547510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.taap.2019.01.012","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T05:48:12Z","timestamp":1547531292000},"page":"54-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["A multiplexed UPLC-MS\/MS assay for the simultaneous measurement of urinary safety biomarkers of drug-induced kidney injury and phospholipidosis"],"prefix":"10.1016","volume":"366","author":[{"given":"Elizabeth","family":"Tengstrand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2019.01.012_bb0005","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.taap.2006.10.015","article-title":"Biomarkers to monitor drug-induced phospholipidosis","volume":"218","author":"Baronas","year":"2007","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2019.01.012_bb0010","doi-asserted-by":"crossref","first-page":"308594","DOI":"10.1155\/2012\/308594","article-title":"Phospholipogenic pharmaceuticals are associated with a higher incidence of histological findings than nonphospholipogenic pharmaceuticals in preclinical toxicology studies","volume":"2012","author":"Barone","year":"2012","journal-title":"J. Toxicol."},{"key":"10.1016\/j.taap.2019.01.012_bb0015","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.4155\/bio.11.165","article-title":"Case studies from the use of commercial biomarker\/protein test kits","volume":"16","author":"Beaver","year":"2011","journal-title":"Bioanalysis"},{"key":"10.1016\/j.taap.2019.01.012_bb0020","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/01926230701196414","article-title":"Letter to the editor","volume":"35","author":"Berridge","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.taap.2019.01.012_bb0025","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF01813904","article-title":"Enzyme activities and phospholipid storage patterns in brain and spleen samples from Niemann-Pick disease variants: a comparison of neuropathic and non-neuropathic forms","volume":"9","author":"Besley","year":"1986","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.taap.2019.01.012_bb0030","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nbt0510-436","article-title":"Next-generation biomarkers for detecting kidney toxicity","volume":"28","author":"Bonventre","year":"2010","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.taap.2019.01.012_bb0035","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1074\/mcp.M113.036095","article-title":"Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach","volume":"13","author":"Carr","year":"2014","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.taap.2019.01.012_bb0040","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1177\/0192623309352496","article-title":"A strategy for risk management of drug-induced phospholipidosis","volume":"37","author":"Chatman","year":"2009","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.taap.2019.01.012_bb0045","author":"Critical Path Institute"},{"key":"10.1016\/j.taap.2019.01.012_bb0050","author":"Critical Path Institute"},{"issue":"1","key":"10.1016\/j.taap.2019.01.012_bb0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4067\/S0717-95022009000100011","article-title":"Gentamicin induces renal morphopathology in Wistar rats","volume":"27","author":"De Souza","year":"2009","journal-title":"Int. J. Morphol."},{"key":"10.1016\/j.taap.2019.01.012_bb0060","author":"EMA (European Medicines Agency)"},{"key":"10.1016\/j.taap.2019.01.012_bb0065","author":"EMA (European Medicines Agency)"},{"key":"10.1016\/j.taap.2019.01.012_bb0070","author":"EMA (European Medicines Agency)"},{"key":"10.1016\/j.taap.2019.01.012_bb0075","author":"EMA (European Medicines Agency)"},{"key":"10.1016\/j.taap.2019.01.012_bb0080","author":"FDA (U.S. Food and Drug Administration)"},{"key":"10.1016\/j.taap.2019.01.012_bb0085","author":"FDA (U.S. Food and Drug Administration)"},{"key":"10.1016\/j.taap.2019.01.012_bb0090","author":"FDA (U.S. Food and Drug Administration)"},{"key":"10.1016\/j.taap.2019.01.012_bb0095","author":"FDA (U.S. Food and Drug Administration)"},{"key":"10.1016\/j.taap.2019.01.012_bb0100","author":"FDA (U.S. Food and Drug Administration)"},{"key":"10.1016\/j.taap.2019.01.012_bb0105","author":"FDA (U.S. Food and Drug Administration) Biomarker Qualification Review Team (BQRT) of the Center for Drug Evaluation and Research"},{"key":"10.1016\/j.taap.2019.01.012_bb0110","author":"FDA (U.S. Food and Drug Administration), Center for Drug Evaluation and Research"},{"key":"10.1016\/j.taap.2019.01.012_bb0115","author":"FDA (U.S. Food and Drug Administration), Center for Drug Evaluation and Research"},{"key":"10.1016\/j.taap.2019.01.012_bb0120","author":"FDA (U.S. Food and Drug Administration), Center for Drug Evaluation and Research"},{"key":"10.1016\/j.taap.2019.01.012_bb0125","author":"FDA (U.S. Food and Drug Administration), Center for Drug Evaluation and Research Division of Cardiovascular and Renal Products"},{"issue":"4","key":"10.1016\/j.taap.2019.01.012_bb0130","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1208\/s12248-011-9301-x","article-title":"Biomarkers for drug-induced renal damage and nephrotoxicity \u2013 an overview for applied toxicology","volume":"13","author":"Fuchs","year":"2011","journal-title":"AAPS J."},{"issue":"9","key":"10.1016\/j.taap.2019.01.012_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jid.2013.287","article-title":"Enzyme immunoassay and enzyme-linked immunosorbent assay","volume":"133","author":"Gan","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.taap.2019.01.012_bb8855","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1177\/0192623313520352","article-title":"Normal ranges and variability of novel urinary renal biomarkers in Sprague-Dawley rats: comparison of constitutive values between males and females and across assay platforms","volume":"42","author":"Gautier","year":"2014","journal-title":"Toxicol. Pathol."},{"issue":"2","key":"10.1016\/j.taap.2019.01.012_bb0145","first-page":"199","article-title":"Studies on lipids from the liver and spleen of a child (O.L.) with Niemann-Pick's disease type C","volume":"22","author":"Harder","year":"1984","journal-title":"J. Clin. Chem. Clin. Biochem."},{"key":"10.1016\/j.taap.2019.01.012_bb0150","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/toxsci\/kfr112","article-title":"Biological qualification of biomarkersof chemical-induced renal toxicity in two strains of male rat","volume":"122","author":"Harpur","year":"2011","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.taap.2019.01.012_bb0155","first-page":"1","article-title":"Multiplex immunoassays in clinical bioanalysis: the promise and challenges to implementation in clinical development","volume":"37","author":"Hidi","year":"2010","journal-title":"Life Sci. Tech. Bull."},{"key":"10.1016\/j.taap.2019.01.012_bb0160","first-page":"24","article-title":"Drug-induced phospholipidosis assessment from nonclinical to clinical studies","volume":"17","author":"Hsieh","year":"2015","journal-title":"Dokusei Shitsumon-Bako."},{"issue":"1","key":"10.1016\/j.taap.2019.01.012_bb0170","first-page":"239","article-title":"Gentamicin or chlorphentermine induction of phospholipidosis in the developing organism: role of tissue species in manifestation of toxicity","volume":"232","author":"Kacew","year":"1984","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2019.01.012_bb0175","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF02532199","article-title":"Bis-(monoacylglycerol)phosphate and acyl phosphatidylglycerol isolated from human livers of lipidosis induced by 4,4\u2032-diethyl-aminoethoxyhexestrol","volume":"9","author":"Kasama","year":"1974","journal-title":"Lipids"},{"issue":"4","key":"10.1016\/j.taap.2019.01.012_bb0180","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrd2006","article-title":"Multiplexed protein measurement: technologies and applications of protein and antibody arrays","volume":"5","author":"Kingsmore","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.taap.2019.01.012_bb0185","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.taap.2014.06.014","article-title":"Di-22:6-bis(monoacylglycerol)phosphate: a clinical biomarker of drug-induced phospholipidosis for drug development and safety assessment","volume":"279","author":"Liu","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"3","key":"10.1016\/j.taap.2019.01.012_bb0190","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/0192623311432290","article-title":"Phospholipidosis in rats treated with amiodarone: serum biochemistry and whole genome micro-array analysis supporting the lipid traffic jam hypothesis and the subsequent rise of the biomarker BMP","volume":"40","author":"Mesens","year":"2012","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.taap.2019.01.012_bb0195","article-title":"Urinary LBPA tracks with onset and reversal of drug-induced phospholipidosis","author":"Philips","year":"2009","journal-title":"Soc. Toxicol. Abstr."},{"issue":"2","key":"10.1016\/j.taap.2019.01.012_bb9955","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/toxsci\/kfw038","article-title":"Rat urinary osteopontin and neutrophil gelatinase-associated lipocalin improve certainty of detecting drug-induced kidney injury","volume":"151","author":"Phillips","year":"2016","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.taap.2019.01.012_bb0200","author":"PMDA (Pharmaceuticals and Medical Devices Agency of Japan)"},{"issue":"2","key":"10.1016\/j.taap.2019.01.012_bb0205","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/toxsci\/kfq267","article-title":"An integrative overview on the mechanisms underlying the renal tubular cytotoxicity of gentamicin","volume":"119","author":"Quiros","year":"2011","journal-title":"Toxicol. Sci."},{"issue":"3","key":"10.1016\/j.taap.2019.01.012_bb0210","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF02531203","article-title":"Accumulation of glycerophospholipid in classical Niemann-Pick disease","volume":"3","author":"Rouser","year":"1968","journal-title":"Lipids"},{"key":"10.1016\/j.taap.2019.01.012_bb0215","author":"Safer and Faster Evidence-based Translation (SAFE-T) Consortium"},{"issue":"3","key":"10.1016\/j.taap.2019.01.012_bb0220","first-page":"91","article-title":"Clinical and biochemical investigation of make patients exhibiting membranous cytoplasmic bodies in biopsied kidney tissues; a pitfall in diagnosis of Fabry disease","volume":"4","author":"Sakuraba","year":"2015","journal-title":"J. Nephropathol."},{"key":"10.1016\/j.taap.2019.01.012_bb0225","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0022-2275(20)41642-6","article-title":"Structure and function of lamellar bodies, lipid protein complexes involved in storage and secretion of cellular lipids","volume":"32","author":"Schmitz","year":"1991","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.taap.2019.01.012_bb0230","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/qjmed\/hcp143","article-title":"Gentamicin-associated acute kidney injury","volume":"102","author":"Selby","year":"2009","journal-title":"Q. J. Med."},{"key":"10.1016\/j.taap.2019.01.012_bb0235","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbalip.2012.08.013","article-title":"Drug induced phospholipidosis: an acquired lysosomal storage disorder","volume":"1831","author":"Shayman","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.taap.2019.01.012_bb0240","article-title":"UPLC\u2122: an introduction and review","author":"Swartz","year":"2007","journal-title":"J. Liq. Chromatogr."},{"key":"10.1016\/j.taap.2019.01.012_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41021-015-0001-0","article-title":"ILSI Health and Environmental Sciences Institute (HESI), global leader in advancing translational science to create science-based solutions for a sustainable, healthier world","volume":"37","author":"Takei","year":"2015","journal-title":"Genes Environ."},{"key":"10.1016\/j.taap.2019.01.012_bb0250","series-title":"Emerging translatable safety biomarkers. Comprehensive Medicinal Chemistry III","first-page":"255","author":"Tarrant","year":"2017"},{"issue":"5","key":"10.1016\/j.taap.2019.01.012_bb0255","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1517\/17425251003601961","article-title":"Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities","volume":"6","author":"Tengstrand","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"1","key":"10.1016\/j.taap.2019.01.012_bb0260","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1091581811430167","article-title":"Comparison of the diagnostic accuracy of di-22:6-bis(monoacylglycerol)phosphate and other urinary phospholipids for drug-induced phospholipidosis or tissue injury in the rat","volume":"31","author":"Thompson","year":"2012","journal-title":"Int. J. Toxicol."},{"issue":"2","key":"10.1016\/j.taap.2019.01.012_bb0265","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.toxlet.2012.07.013","article-title":"Comparison of urinary and serum levels of di-22:6-bis(monoacylglycerol)phosphate as noninvasive biomarkers of phospholipidosis in rats","volume":"213","author":"Thompson","year":"2012","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.taap.2019.01.012_bb0270","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3109\/15563650.2011.615319","article-title":"Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury","volume":"49","author":"Waring","year":"2011","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.taap.2019.01.012_bb0275","series-title":"Presented at the Society of Toxicology Pathology (STP) Continuing Education Course on Drug-Induced Phospholipidosis","article-title":"FDA phospholipidosis working group preliminary results and developing opinions","author":"Willard","year":"2008"},{"key":"10.1016\/j.taap.2019.01.012_bb0280","series-title":"Presented at the FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting","article-title":"PLWG activities on phospholipidosis: data mining, modeling and laboratory research","author":"Willard","year":"2010"},{"key":"10.1016\/j.taap.2019.01.012_bb0285","series-title":"Lysosomes: Biology, Diseases, and Therapeutics","first-page":"487","article-title":"Lysosomes and phospholipidosis in drug development and regulation","author":"Willard","year":"2016"},{"key":"10.1016\/j.taap.2019.01.012_bb0290","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0041-008X(81)90413-0","article-title":"Gentamicin nephrotoxicity 1. Acute biochemical correlates in rats","volume":"61","author":"Williams","year":"1981","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"10.1016\/j.taap.2019.01.012_bb0295","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/104063871102300219","article-title":"Assessment of urine solute and matrix effects on the performance of an enzyme-linked immunosorbent assay for measurement of interleukin-6 in dog urine","volume":"23","author":"Wood","year":"2011","journal-title":"J. Vet. Diagn. Investig."},{"key":"10.1016\/j.taap.2019.01.012_bb0300","author":"Wuhan Fine Biological Technology Co"},{"issue":"3","key":"10.1016\/j.taap.2019.01.012_bb0305","first-page":"613","article-title":"Drug-induced lipidosis in human cases and in animal experiments: accumulation of an acidic glycerophospholipid","volume":"69","author":"Yamamoto","year":"1971","journal-title":"J. Biochem."},{"issue":"5","key":"10.1016\/j.taap.2019.01.012_bb0310","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/oxfordjournals.jbchem.a129695","article-title":"Studies on drug-induced lipidosis: III. Lipid composition of the liver and some other tissues in clinical cases of \u201cNiemann-Pick-like-syndrome\u201d induced by 4,4\u2032-diethylaminoethoxyhexesterol","volume":"70","author":"Yamamoto","year":"1971","journal-title":"J. Biochem."},{"issue":"6","key":"10.1016\/j.taap.2019.01.012_bb0315","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M110.006593","article-title":"Methods for peptide and protein quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry","volume":"10","author":"Zhang","year":"2011","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.taap.2019.01.012_bb0320","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cca.2012.09.022","article-title":"Analytical and biological validation of a multiplex immunoassay for acute kidney injury biomarkers","volume":"415","author":"Zhang","year":"2013","journal-title":"Clin. Chim. Acta"},{"issue":"1","key":"10.1016\/j.taap.2019.01.012_bb0325","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/toxsci\/kfm260","article-title":"Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium","volume":"101","author":"Zhou","year":"2008","journal-title":"Toxicol. Sci."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X19300201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X19300201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T06:55:40Z","timestamp":1662792940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X19300201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":65,"alternative-id":["S0041008X19300201"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2019.01.012","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multiplexed UPLC-MS\/MS assay for the simultaneous measurement of urinary safety biomarkers of drug-induced kidney injury and phospholipidosis","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2019.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Nextcea Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}